[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Nanjing Medical University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":611},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,35,0,25,[9,45,66,91,120,142,169,196,224,246,267,290,316,341,362,387,410,432,455,479,501,523,550,570,592],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100643562","health-behavior-intervention-for-colorectal-cancer-patients-100643562",false,"NCT07632313","Health Behavior Intervention for Colorectal Cancer Patients","A Study on Health Behavior Intervention for Colorectal Cancer Patients Based on the Theory of Time-bound Self-regulation","Inclusion Criteria:\n\nAge ≥ 18 years; patients who meet the diagnostic criteria for colorectal cancer outlined in the \"Chinese Guidelines for the Diagnosis and Treatment of Colorectal Cancer (2023 Edition)\" and for whom the time since surgery is ≥ 3 months; patients who are able to understand the study and complete the questionnaire independently; and patients who voluntarily agree to participate.\n\nExclusion Criteria:\n\nPatients with severe cardiac, hepatic, or renal insufficiency or other serious systemic diseases; patients with cognitive or psychiatric disorders; patients with severe postoperative complications (such as anastomotic leakage or severe wound infection); patients with metastatic cancer or concurrent malignant tumors; patients with a life expectancy of less than 6 months.","ALL","18 Years","75 Years",{"count":21,"type":22},40,"ESTIMATED","INTERVENTIONAL",[25],"NA","Develop a health behavior intervention plan based on patients' needs and preferences, and preliminarily apply and evaluate the feasibility and effectiveness of this intervention plan for patients with colorectal cancer.",[28],"Colorectal Cancer",[30,31],"health behavior","Temporal Self-Regulation Theory","NOT_YET_RECRUITING","2026-06-02",{"date":35,"type":36},"2026-06-08","ACTUAL",{"date":38,"type":22},"2026-06-15",{"date":40,"type":22},"2027-01-30",{"name":42,"class":43},"Nanjing Medical University","OTHER",1,{"id":46,"slug":47,"hasResults":12,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":51,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":23,"phases":54,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":63,"leadSponsor":65,"locationsCount":44},"100639758","using-single-and-combined-nudge-strategies-to-promote-healthier-beverage-intake-among-college-students-100639758","NCT07625969","Using Single and Combined Nudge Strategies to Promote Healthier Beverage Intake Among College Students","Inclusion Criteria:\n\n* college students\n* willing to participate\n\nExclusion Criteria:\n\nnone",true,{"count":53,"type":22},1000,[25],"The primary objective of this study was to examine whether three nudging strategies influence beverage consumption behavior among Chinese university students. These interventions included health warning messages, hedonic labeling, and a combination of health warning and hedonic labeling. A between-subjects experimental design with a single factor was employed to assess the effects of these strategies on students' choices between sugar-sweetened and sugar-free beverages, thereby evaluating their effectiveness in promoting healthier beverage selections.",[57,58],"Obesity","Food Selection","2026-05-29",{"date":61,"type":36},"2026-06-04",{"date":59,"type":22},{"date":64,"type":22},"2026-06-10",{"name":42,"class":43},{"id":67,"slug":68,"hasResults":12,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":4,"eligibilityCriteria":72,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":73,"enrollmentInfo":74,"targetDuration":4,"studyType":23,"phases":76,"briefSummary":77,"conditions":78,"keywords":81,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":44},"100637397","perioperative-vericiguat-in-patients-undergoing-cardiovascular-surgery-100637397","NCT07594509","Perioperative Vericiguat in Patients Undergoing Cardiovascular Surgery","A Multicenter, Randomized, Controlled Trial to Evaluate the Efficacy and Safety of Perioperative Vericiguat in Patients Undergoing Cardiovascular Surgery","Inclusion Criteria:\n\n* Aged 18 to 80 years, any sex;\n* Scheduled to undergo cardiovascular surgery at the study centers, including coronary artery bypass grafting (CABG), heart valve replacement\u002Frepair, and great vessel surgery;\n* Preoperative evaluation indicates a high risk of heart failure or confirmed cardiac dysfunction;\n* Systolic blood pressure (SBP) \\>= 100 mmHg;\n* Expected to complete the 6-month postoperative follow-up;\n* Signed written informed consent by the patient or their authorized representative.\n\nExclusion Criteria:\n\n* Current use of other sGC stimulators or phosphodiesterase type 5 (PDE-5) inhibitors (e.g., sildenafil, tadalafil);\n* Severe hypotension (symptomatic hypotension or resting SBP \\\u003C 90 mmHg);\n* Severe hepatic or renal dysfunction (Hepatic: Child-Pugh class C, or ALT\u002FAST \\> 3 times the upper limit of normal; Renal: eGFR \\\u003C 15 mL\u002Fmin\u002F1.73m\\^2, or requiring chronic dialysis);\n* Malignant tumors, severe hematological diseases, or severe malnutrition (albumin \\\u003C 25 g\u002FL);\n* Known allergy to vericiguat or placebo components;\n* Pregnant or lactating women, or those planning to become pregnant during the study period;\n* Currently participating in other interventional clinical trials;\n* Moderate to severe cognitive impairment without a fixed guardian, unable to cooperate with treatment and follow-up;\n* Confirmed severe infection, sepsis, or septic shock preoperatively.","80 Years",{"count":75,"type":22},600,[25],"The purpose of this study is to evaluate the efficacy and safety of perioperative vericiguat in patients undergoing cardiovascular surgery. Patients at high risk of heart failure or with confirmed cardiac dysfunction will be randomly assigned to receive either vericiguat plus standard of care or standard of care alone. The primary objective is to determine whether perioperative administration of vericiguat can reduce (I) the Incidence of Early Postoperative Hemodynamic Deterioration or Clinically Significant Myocardial Injury; (II) Incidence of Major Sterile Inflammation-Related Organ Injuries (MSIRI), and the incidence of Major Adverse Cardiovascular Events (MACE) within 12 months after surgery.",[79,80],"Cardio Vascular Disease","Cardiopulmonary Bypass",[82],"cardiovascular","2026-05-11",{"date":85,"type":36},"2026-05-18",{"date":87,"type":22},"2026-05-31",{"date":89,"type":22},"2030-12-31",{"name":42,"class":43},{"id":92,"slug":93,"hasResults":12,"nctId":94,"briefTitle":95,"officialTitle":95,"acronym":4,"eligibilityCriteria":96,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":97,"enrollmentInfo":98,"targetDuration":4,"studyType":23,"phases":100,"briefSummary":101,"conditions":102,"keywords":104,"overallStatus":111,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":44},"100636416","effects-and-mechanisms-of-transcranial-direct-current-stimulation-combined-with-dialectical-behavior-therapy-skills-training-in-adults-with-attention-deficithyperactivity-disorder-100636416","NCT07565402","Effects and Mechanisms of Transcranial Direct Current Stimulation Combined With Dialectical Behavior Therapy Skills Training in Adults With Attention-Deficit\u002FHyperactivity Disorder","Inclusion Criteria:\n\n* Meet the diagnostic criteria for attention-deficit\u002Fhyperactivity disorder (ADHD) according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5). Diagnosis confirmed using the Chinese version of the Diagnostic Interview for ADHD in Adults (DIVA-5).\n* Aged between 18 and 55 years.\n* Right-handed.\n* Voluntary participation with provision of written informed consent.\n\nExclusion Criteria:\n\n* Presence of neurological disorders or other psychiatric disorders.\n* Severe physical illness.\n* Receipt of electroconvulsive therapy (ECT) or other physical treatments within 6 months prior to enrollment.\n* Planned changes in ADHD-related medication before the final follow-up assessment.\n* Contraindications to tDCS (e.g., intracranial metal or electronic implants, skull plates, or other cranial implants).\n* Pregnancy or breastfeeding.","55 Years",{"count":99,"type":22},60,[25],"Effects and Mechanisms of Transcranial Direct Current Stimulation Combined with Dialectical Behavior Therapy Skills Training in Adults with Attention-Deficit\u002FHyperactivity Disorder\n\nAbstract Adult attention-deficit\u002Fhyperactivity disorder (ADHD) is a neurodevelopmental disorder that frequently persists into adulthood and is associated with substantial impairments in academic, occupational, and social functioning. Although pharmacological treatment remains the primary intervention, some adults with ADHD show limited response to medication or experience adverse effects, highlighting the need for effective non-pharmacological or combined treatment approaches. Dialectical Behavior Therapy Skills Training (DBT-ST), which emphasizes emotion regulation, impulse control, mindfulness, and behavioral organization, has shown potential in the treatment of adult ADHD. However, its therapeutic efficacy may vary across individuals, and strategies to enhance treatment outcomes still require further investigation. In parallel, transcranial direct current stimulation (tDCS), a safe and non-invasive neuromodulation technique, has attracted increasing attention as an adjunctive intervention in psychiatric disorders. Existing studies suggest that combining tDCS with psychotherapy may optimize treatment effects by modulating neural networks related to cognitive control and emotional regulation. Nevertheless, evidence for such combined interventions in adult ADHD remains limited, particularly with respect to rigorous randomized controlled designs and mechanism-based neuroimaging validation.\n\nThe present study aims to investigate the efficacy and potential mechanisms of tDCS combined with DBT-ST in adults with ADHD. A randomized, double-blind, sham-controlled design will be adopted. Sixty eligible adult participants with ADHD will be randomly assigned to either an active tDCS group or a sham stimulation group, with both groups receiving weekly DBT-ST for ten consecutive weeks. tDCS will be administered over the bilateral dorsolateral prefrontal cortex (DLPFC) with 2 mA current for 20 minutes, prior to each group therapy session. Clinical symptoms, functional outcomes, and cognitive performance will be assessed at baseline, post-intervention, and one-month follow-up using standardized self-report measures and behavioral tasks. In addition, resting-state functional magnetic resonance imaging (rs-fMRI) will be conducted before and after the intervention to examine changes in functional connectivity within prefrontal regulatory networks.\n\nThis study is expected to clarify whether tDCS can enhance the therapeutic effects of DBT-ST on core ADHD symptoms and related functional outcomes, and whether such effects are associated with improvements in executive function, emotion regulation, and alterations in DLPFC-related resting-state functional connectivity. By integrating clinical, behavioral, and neuroimaging measures, the study seeks to provide preliminary evidence for a novel non-pharmacological combined intervention for adult ADHD and to further elucidate its underlying neural mechanisms.",[103],"Adult Attention Deficit Hyperactivity Disorder",[105,106,107,108,109,110],"adult ADHD","transcranial direct current stimulation","dialectical behavior therapy","DBT skills training","executive function","resting-state fMRI","RECRUITING","2026-04-27",{"date":114,"type":36},"2026-05-04",{"date":116,"type":22},"2026-04-01",{"date":118,"type":22},"2028-09-01",{"name":42,"class":43},{"id":121,"slug":122,"hasResults":12,"nctId":123,"briefTitle":124,"officialTitle":125,"acronym":4,"eligibilityCriteria":126,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":127,"targetDuration":4,"studyType":23,"phases":128,"briefSummary":129,"conditions":130,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":134,"lastUpdatePostDateStruct":135,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":4},"100635767","exercise-and-mindfulness-intervention-for-chemotherapy-induced-peripheral-neuropathy-in-patients-with-cancer-100635767","NCT07556965","Exercise and Mindfulness Intervention for Chemotherapy-Induced Peripheral Neuropathy in Patients With Cancer","Effect of an Exercise- and Mindfulness-Based Cognitive Therapy Intervention on Physical and Psychological Symptoms in Cancer Patients With Chemotherapy-Induced Peripheral Neuropathy","Inclusion Criteria:\n\n* Patients with a pathologically confirmed malignant tumor;\n* Currently receiving neurotoxic chemotherapy and experiencing chemotherapy-induced peripheral neuropathy (CIPN);\n* Cancer stage Tis or stage I-III;\n* Aged 18 years or older, with normal consciousness, mental status, and verbal communication ability; able to understand and judge their own sensations and general condition; and able to complete the questionnaires;\n* Willing to participate in the study and able to provide written informed consent;\n* Patients with NCI-CTCAE grade \\\u003C2 who are considered suitable for exercise intervention.\n\nExclusion Criteria:\n\n* Presence of other neurological diseases or severe psychiatric disorders;\n* Presence of other serious illnesses, such as severe heart disease or respiratory failure;\n* Inability to understand or complete the questionnaires;\n* Participation in psychological counseling, psychotherapy, or other clinical trials within the past 6 months;\n* Inability or expected inability to complete the full 6-week intervention.",{"count":21,"type":22},[25],"The goal of this clinical trial is to learn whether an exercise- and mindfulness-based cognitive therapy intervention can improve physical and psychological symptoms in cancer patients with chemotherapy-induced peripheral neuropathy. It will also examine whether this intervention can improve quality of life. The main questions it aims to answer are:\n\nCan this intervention reduce physical symptoms related to chemotherapy-induced peripheral neuropathy? Can this intervention reduce psychological symptoms in affected patients? Can this intervention improve patients' quality of life?\n\nParticipants will:\n\nFollow a structured program of regular exercise and mindfulness practice Undergo weekly assessments of symptom changes Keep records of their symptom changes during the intervention period",[131,132,133],"Cancer Patients","Chemotherapy-Induced Peripheral Neuropathy","Exercise Intervention","2026-04-22",{"date":136,"type":36},"2026-04-29",{"date":138,"type":22},"2026-04-20",{"date":140,"type":22},"2027-06-30",{"name":42,"class":43},{"id":143,"slug":144,"hasResults":12,"nctId":145,"briefTitle":146,"officialTitle":147,"acronym":4,"eligibilityCriteria":148,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":149,"enrollmentInfo":150,"targetDuration":4,"studyType":23,"phases":152,"briefSummary":155,"conditions":156,"keywords":158,"overallStatus":111,"whyStopped":4,"lastUpdateSubmitDate":162,"lastUpdatePostDateStruct":163,"startDateStruct":165,"completionDateStruct":166,"leadSponsor":168,"locationsCount":44},"100635154","phase-2-open-label-study-of-dimethyl-fumarate-in-adults-with-type-1-diabetes-100635154","NCT07548996","Open-Label Study of Dimethyl Fumarate in Adults With Type 1 Diabetes","Non-Randomized, Parallel-Controlled, Single-Center, Open-Label Clinical Trial Evaluating the Efficacy and Safety of Dimethyl Fumarate in Preserving Pancreatic β-Cell Function in Adults With Type 1 Diabetes","Inclusion Criteria:\n\n* Willing and able to participate in the study and provide signed informed consent\n* Aged 18 to 65 years\n* Diagnosed with type 1 diabetes mellitus according to ADA 2024 criteria\n* Positive for at least 2 islet autoantibodies among insulin autoantibody (IAA), glutamic acid decarboxylase autoantibody (GADA), insulinoma-associated protein 2 autoantibody (IA-2A), islet cell antibody (ICA), and zinc transporter 8 autoantibody (ZnT8A)\n* Random C-peptide level greater than or equal to 200 pmol\u002FL\n\nNote:\n\n\\- For participants who have used insulin for more than 14 days, a positive IAA result must be accompanied by at least 2 additional positive autoantibodies other than IAA\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding women, positive urine pregnancy test at screening, or inability to rule out pregnancy in the opinion of the investigator\n* Good glycemic control with oral antidiabetic drugs alone\n* Participation in other studies involving diabetes treatment or immunomodulation\n* Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) greater than 3 times the upper limit of normal\n* Renal insufficiency or evidence of kidney damage, including estimated glomerular filtration rate (eGFR) less than 60 mL\u002Fmin\u002F1.73 m², urinary albumin-to-creatinine ratio (UACR) greater than or equal to 3.4 mg\u002Fmmol (repeat confirmation if necessary), or other kidney disease considered unsuitable for enrollment by the investigator\n* History of malignancy, uncontrolled immune system disease, or uncontrolled infection\n* Alcohol abuse, drug abuse, psychiatric disorder, or other conditions considered unsuitable for participation in a drug trial\n* Use of other immunosuppressive agents within 12 weeks before enrollment\n* Participation in any other drug trial within 12 weeks before enrollment\n* History of multiple drug allergies, allergic diseases, hypersensitivity constitution, or drug dependence\n* Any disease or condition that, in the opinion of the investigator, may interfere with study participation or evaluation","65 Years",{"count":151,"type":22},96,[153,154],"PHASE2","PHASE3","This is a non-randomized, parallel-controlled, single-center, open-label clinical trial designed to evaluate the efficacy of dimethyl fumarate in preserving pancreatic beta-cell function in adults with type 1 diabetes, as well as its safety and tolerability in this population.\n\nEligible participants are adults aged 18 to 65 years who meet the ADA 2024 diagnostic criteria for type 1 diabetes, have at least 2 positive islet autoantibodies, and have residual beta-cell function as evidenced by a random C-peptide level of at least 200 pmol\u002FL. A total of 96 participants are planned for enrollment, including 32 in the dimethyl fumarate treatment group and 64 in the standard-treatment control group.\n\nParticipants in the treatment group will receive dimethyl fumarate enteric-coated capsules in addition to standard insulin therapy for type 1 diabetes. Dimethyl fumarate will be initiated at 120 mg twice daily and increased after 7 days to a maintenance dose of 240 mg twice daily. Participants in the control group will receive standard insulin therapy alone. The intervention period will be 24 weeks, followed by 52 weeks of follow-up.\n\nThe primary efficacy endpoint is the baseline-adjusted geometric mean area under the serum C-peptide curve during a 2-hour mixed-meal tolerance test at Week 24. Secondary endpoints include measures of beta-cell function at multiple time points, changes in glycated hemoglobin, proportions of participants with good or poor glycemic control, insulin dose requirements, and immunologic markers including lymphocyte subsets, cytokine profiles, and islet autoantibody characteristics. Safety assessments will include the incidence of flushing, gastrointestinal adverse events, allergic reactions, opportunistic infections, liver function abnormalities, lymphopenia, renal abnormalities, hypoglycemia, severe hypoglycemia, ketosis, and ketoacidosis.\n\nThe total study duration is 36 months, from January 2026 to December 2028.",[157],"Type 1 Diabetes Mellitus",[159,160,161],"Dimethyl Fumarate","Type 1 Diabetes","Beta-Cell Function","2026-04-21",{"date":164,"type":36},"2026-04-23",{"date":112,"type":22},{"date":167,"type":22},"2028-12-31",{"name":42,"class":43},{"id":170,"slug":171,"hasResults":12,"nctId":172,"briefTitle":173,"officialTitle":174,"acronym":4,"eligibilityCriteria":175,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":176,"enrollmentInfo":177,"targetDuration":179,"studyType":180,"phases":4,"briefSummary":181,"conditions":182,"keywords":184,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":188,"lastUpdatePostDateStruct":189,"startDateStruct":191,"completionDateStruct":193,"leadSponsor":195,"locationsCount":4},"100630961","risk-assessment-of-pancreatic-islet-autoimmunity-in-patients-with-aitd-100630961","NCT07494474","Risk Assessment of Pancreatic Islet Autoimmunity in Patients With AITD","Autoimmune Thyroid Disease Patients Identification and Assessment of Pancreatic Islet Autoimmune Risk","Inclusion criteria：\n\n1. Voluntary participation and signed informed consent\n2. Age 18-60 years\n3. Diagnosed with autoimmune thyroid disease, with positivity for at least one autoantibody: TPOAb, TgAb, TRAb, or TSI Exclusion criteria：\n\n1: Previously diagnosed diabetes mellitus or current diabetes treatment 2: Conditions severely affecting glucose metabolism (e.g., Cushing's syndrome, acromegaly) 3: Use of immunosuppressants or high-dose glucocorticoids within the past 3 months 4: Pregnancy or lactation 5: Severe cardiac, hepatic, or renal dysfunction, or any condition unsuitable for participation","60 Years",{"count":178,"type":22},834,"2 Months","OBSERVATIONAL","This study aims to evaluate the risk of islet autoimmunity in patients with autoimmune thyroid disease (AITD), describe related clinical and laboratory characteristics, and explore the development of a risk assessment model based on clinical, laboratory, and genetic markers. Adults aged 18-60 years with confirmed AITD will undergo baseline assessment including demographic data, anthropometric measures, lifestyle factors, medical history, thyroid-related clinical information, thyroid function, and thyroid antibody testing. A baseline blood sample will be collected for measurement of islet autoantibodies (GADA, IA-2A, ZnT8A, and IAA). Participants with positive islet autoantibodies will undergo further evaluation of glucose metabolism and beta-cell function, including HbA1c, OGTT, insulin, and C-peptide testing. Genome-wide genetic data will be used to construct a type 1 diabetes-related genetic risk score, and additional HLA genotyping may be performed in autoantibody-positive participants. The study will assess the prevalence and profile of islet autoantibodies in AITD and identify clinical, laboratory, and genetic factors associated with islet autoantibody positivity.",[183],"Autoimmune Thyroid Disease",[185,186,187],"AITD","Islet autoantibodies","type 1 diabetes","2026-03-20",{"date":190,"type":36},"2026-03-27",{"date":192,"type":22},"2026-08-31",{"date":194,"type":22},"2028-04-30",{"name":42,"class":43},{"id":197,"slug":198,"hasResults":12,"nctId":199,"briefTitle":200,"officialTitle":201,"acronym":202,"eligibilityCriteria":203,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":73,"enrollmentInfo":204,"targetDuration":4,"studyType":180,"phases":4,"briefSummary":206,"conditions":207,"keywords":209,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":216,"lastUpdatePostDateStruct":217,"startDateStruct":219,"completionDateStruct":221,"leadSponsor":223,"locationsCount":4},"100630061","tumor-microenvironment-changes-after-neoadjuvant-chemo-immunotherapy-in-esophageal-squamous-cell-carcinoma-100630061","NCT07482774","Tumor Microenvironment Changes After Neoadjuvant Chemo-Immunotherapy in Esophageal Squamous Cell Carcinoma","Dynamic Characterization of Tumor Microenvironment Remodeling and Immune Escape After Neoadjuvant Chemo-Immunotherapy in Esophageal Squamous Cell Carcinoma Using Single-Cell and Spatial Transcriptomics","TME-ESCC","Inclusion Criteria:\n\nAge 18 to 80 years; Pathologically confirmed esophageal squamous cell carcinoma; Potentially resectable disease and planned to receive standard neoadjuvant chemotherapy combined with immunotherapy followed by surgery; ECOG performance status 0 to 2; Adequate major organ function as judged by the investigator; Willing to provide tumor tissue samples at baseline and at the time of surgery; peripheral blood samples may also be collected when feasible; Written informed consent provided;\n\nExclusion Criteria:\n\nPrior treatment with immune checkpoint inhibitors; Active infection, immunodeficiency, or autoimmune disease requiring systemic immunosuppressive therapy; Pregnancy or breastfeeding; Contraindications to study-related tissue sampling or planned surgery; Inability to comply with study procedures or follow-up;",{"count":205,"type":22},12,"This prospective observational study aims to characterize dynamic changes in the tumor microenvironment of patients with esophageal squamous cell carcinoma receiving standard neoadjuvant chemotherapy combined with immunotherapy followed by surgical resection. Paired tumor tissue samples will be collected before treatment and at surgery, and peripheral blood samples may also be collected when feasible. Single-cell RNA sequencing and spatial transcriptomics will be used to evaluate changes in cellular composition, transcriptional states, and spatial organization within the tumor microenvironment and to explore their associations with pathological response.",[208],"Esophageal Squamous Cell Carcinoma",[210,211,212,213,214,215],"Tumor Microenvironment","Neoadjuvant Chemoimmunotherapy","Single-Cell RNA Sequencing","Spatial Transcriptomics","Pathological Response","Immune Escape","2026-03-16",{"date":218,"type":36},"2026-03-19",{"date":220,"type":22},"2026-06-01",{"date":222,"type":22},"2027-12-31",{"name":42,"class":43},{"id":225,"slug":226,"hasResults":12,"nctId":227,"briefTitle":228,"officialTitle":229,"acronym":4,"eligibilityCriteria":230,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":149,"enrollmentInfo":231,"targetDuration":4,"studyType":23,"phases":233,"briefSummary":234,"conditions":235,"keywords":236,"overallStatus":111,"whyStopped":4,"lastUpdateSubmitDate":239,"lastUpdatePostDateStruct":240,"startDateStruct":242,"completionDateStruct":244,"leadSponsor":245,"locationsCount":44},"100612808","phase-3-clinical-study-for-dimethyl-fumarate-in-preserving-islet--cell-function-in-type-1-diabetes-mellitus-100612808","NCT07258394","Clinical Study for Dimethyl Fumarate in Preserving Islet β-Cell Function in Type 1 Diabetes Mellitus","A Single-Center, Randomized, Double-Blind, Placebo-Controlled Clinical Trial Evaluating the Efficacy and Safety of Dimethyl Fumarate in Preserving Islet β-Cell Function in Patients With Type 1 Diabetes Mellitus","Inclusion Criteria:\n\n1. Subjects who provide written informed consent.\n2. Aged 18-65 years.\n3. Diagnosed with Type 1 Diabetes Mellitus (per ADA 2024 criteria).\n4. Positive for ≥2 autoantibodies: Insulin autoantibody (IAA) Glutamic acid decarboxylase autoantibody (GADA) Protein tyrosine phosphatase antibody (IA-2A) Islet cell antibody (ICA) Zinc transporter 8 autoantibody (ZnT8A) Note: For IAA-positive subjects with insulin use \\>14 days, ≥2 additional autoantibodies must be positive.\n5. Disease duration ≤100 days post-T1DM diagnosis.\n6. Random C-peptide ≥ 200 pmol\u002FL.\n\nExclusion Criteria:\n\n1. Pregnancy, lactation, or women of childbearing potential not using contraception.\n2. Well-controlled glycemia with oral hypoglycemic agents alone.\n3. Participation in other diabetes\u002Fimmune-modulating trials.\n4. ALT\u002FAST \\>3× upper limit of normal (ULN).\n5. History of malignancy, uncontrolled autoimmune disorders, or active infections.\n6. Alcohol\u002Fdrug abuse, psychiatric disorders, or conditions unsuitable for trial participation.\n7. Use of immunosuppressants within 12 weeks prior.\n8. Participation in other drug trials within 12 weeks prior.\n9. History of drug allergies, hypersensitivity, or drug addiction.\n10. Any condition deemed by investigators to compromise study integrity.",{"count":232,"type":22},90,[154],"Purpose of the Clinical Trial:\n\nThis clinical trial aims to investigate whether dimethyl fumarate can treat adults with newly diagnosed type 1 diabetes and to evaluate the safety profile of dimethyl fumarate.\n\nPrimary Research Questions:\n\nDoes dimethyl fumarate protect pancreatic beta-cell function in adults with newly diagnosed type 1 diabetes? What medical issues may arise in individuals taking dimethyl fumarate?\n\nStudy Design:\n\nResearchers will compare dimethyl fumarate with a placebo (an identical substance without active ingredients) to determine whether Dimethyl fumarate can effectively treat type 1 diabetes.\n\nParticipant Activities:\n\nTake dimethyl fumarate or placebo orally twice daily for 24 weeks. Attend on-site visits every 4 weeks during the intervention period and every 12 weeks after the intervention for examinations and assessments.\n\nRecord symptoms, blood glucose control, islet function, and insulin usage throughout the trial.",[160],[160,237,238],"Immunotherapy","Pancreatic Beta-Cell Function","2026-03-03",{"date":241,"type":36},"2026-03-05",{"date":243,"type":36},"2026-01-27",{"date":167,"type":22},{"name":42,"class":43},{"id":247,"slug":248,"hasResults":12,"nctId":249,"briefTitle":250,"officialTitle":251,"acronym":4,"eligibilityCriteria":252,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":253,"targetDuration":4,"studyType":180,"phases":4,"briefSummary":255,"conditions":256,"keywords":258,"overallStatus":111,"whyStopped":4,"lastUpdateSubmitDate":259,"lastUpdatePostDateStruct":260,"startDateStruct":262,"completionDateStruct":264,"leadSponsor":265,"locationsCount":266},"100393128","additive-anti-inflammatory-action-for-aortopathy--arteriopathy-100393128","NCT04398992","Additive Anti-inflammatory Action for Aortopathy & Arteriopathy","Chinese Registry of Additive Anti-inflammatory Action for Aortopathy & Arteriopathy (5A) Protocol: Rationale, Design and Methodology","Inclusion criteria\n\n* Aged 18 years or older.\n* Patients with diagnosis of AAS, including aortic dissection, penetrating aortic ulcer or intramural hematoma.\n* Symptoms started within 14 days from surgery.\n* Patients received medical therapy, open surgical, endovascular, or hybrid repair.\n* Any other major cardiac surgical procedure concomitant with surgery for AAS, such as coronary artery bypass grafting or carotid artery replacement;\n* The patient or guardian agrees to participate in this study. Exclusion criteria\n* Patients aged \\\u003C 18 years.\n* Onset of symptoms \\> 14 days from surgery.\n* AAS secondary to traumatic or iatrogenic injury.\n* Patients who declined participation in registration and follow-up investigation.",{"count":254,"type":22},10000,"Acute aortic syndrome (AAS) is a life-threatening condition. Inflammation plays a key role in the pathogenesis, development and progression of AAS, and is associated with significant mortality and morbidity. Understanding the inflammatory responses and inflammation resolutions is essential for an appropriate management of AAS.\n\nTwenty Chinese cardiovascular centers have collaborated to create a multicenter observational registry (named Chinese registry of Additive Anti-inflammatory Action for Aortopathy \\& Arteriopathy \\[5A\\]), with consecutive enrollment of adult patients who underwent surgery for AAS that was started on Jan 1, 2016 and will be ended on December 31, 2040. Specially, the impact of inflammation and anti-inflammatory strategies on the early and late adverse events are investigated. Primary outcomes are severe systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), Sequential Organ Failure Assessment (SOFA) scores at 7 days following this current surgery. Secondary outcomes are SISR, 30-day mortality, operative mortality, hospital mortality, new-onset stroke, acute kidney injury, surgical site infection, reoperation for bleeding, blood transfusion and length of stay in the intensive care unit.",[257],"Acute Aortic Syndrome",[257],"2026-02-05",{"date":261,"type":36},"2026-02-09",{"date":263,"type":36},"2016-01-01",{"date":89,"type":22},{"name":42,"class":43},34,{"id":268,"slug":269,"hasResults":12,"nctId":270,"briefTitle":271,"officialTitle":272,"acronym":4,"eligibilityCriteria":273,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":73,"enrollmentInfo":274,"targetDuration":4,"studyType":23,"phases":276,"briefSummary":277,"conditions":278,"keywords":280,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":283,"lastUpdatePostDateStruct":284,"startDateStruct":286,"completionDateStruct":287,"leadSponsor":288,"locationsCount":289},"100622342","ai-assisted-subtyping-directed-precision-treatment-in-acute-aortic-dissection-100622342","NCT07382375","AI-assisted Subtyping-directed Precision Treatment in Acute Aortic Dissection","AI-assisted Immunoinflammatory Subtyping-Directed Precision Treatment in Acute Aortic Dissection: A Multicenter RCT-based Exploration","Inclusion Criteria:\n\n1. Confirmed diagnosis of acute aortic dissection by contrast-enhanced Computed Tomography Angiography (CTA) or Magnetic Resonance Angiography (MRA);\n2. Planned emergency surgical treatment (including open surgery and endovascular repair);\n3. Aged 18-80 years old, regardless of gender;\n4. Time from onset to hospital admission ≤ 72 hours;\n5. Signed informed consent form by the patient or their authorized agent, with willingness to cooperate with the follow-up of the study.\n\nExclusion Criteria:\n\n1. Complicated with underlying diseases that affect immunoinflammatory status, such as severe infections (e.g., sepsis, infective endocarditis), autoimmune diseases, malignant tumors, chronic liver diseases, and chronic kidney diseases (uremic stage);\n2. Long-term use of immunosuppressants or glucocorticoids before surgery (continuous use for ≥ 2 weeks);\n3. Pregnant or lactating women;\n4. Patients with mental disorders or cognitive dysfunction who cannot cooperate with the study.",{"count":275,"type":22},300,[25],"Aortic dissection has acute onset and high mortality, with immunoinflammatory response driving lesion progression. Current perioperative anti-inflammatory therapies are mostly empirical and poorly targeted, and AI-assisted typing lacks a complete clinical translation pathway. This study integrates multi-dimensional data to construct an AI immunoinflammatory subtyping system, enabling rapid subtyping and establishing a \"subtyping-target-treatment\" closed loop for emergency needs. Using a prospective multicenter RCT, 300 patients are randomly divided into two groups: the experimental group receives subtyping-based precision therapy, while the control group uses empirical strategies (treatment of physician's choice). It observes 7-day postoperative SOFA score, SIRS and other prognostic indicators to provide evidence-based support for precision treatment.",[279],"Aortic Aneurysm and Dissection",[281,282],"inflammation","immune","2026-01-28",{"date":285,"type":36},"2026-02-02",{"date":222,"type":22},{"date":222,"type":22},{"name":42,"class":43},8,{"id":291,"slug":292,"hasResults":12,"nctId":293,"briefTitle":294,"officialTitle":295,"acronym":296,"eligibilityCriteria":297,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":73,"enrollmentInfo":298,"targetDuration":4,"studyType":23,"phases":299,"briefSummary":300,"conditions":301,"keywords":304,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":308,"lastUpdatePostDateStruct":309,"startDateStruct":311,"completionDateStruct":313,"leadSponsor":314,"locationsCount":315},"100619723","vitamin-b-supplementation-for-patients-undergoing-cardiovascular-surgery-100619723","NCT07348328","Vitamin B Supplementation for Patients Undergoing Cardiovascular Surgery","Vitamin B Supplementation for Patients Undergoing Cardiovascular Surgery: A Randomized Controlled Trial","PANDA XII","Inclusion Criteria:\n\n* Aged 18-80 years, regardless of gender;\n* Scheduled to receive cardiovascular surgery at the research center, including coronary artery bypass grafting (CABG), cardiac valve replacement\u002Frepair, and great vessel surgery;\n* Preoperative assessment indicates that the patient is expected to complete the 6-month postoperative follow-up;\n* The patient or their authorized agent signs a written informed consent form.\n\nExclusion Criteria:\n\n* Regular supplementation with Compound Vitamin B (daily dose ≥ 1.5 times the recommended dietary allowance) or separate supplementation with folic acid, vitamin B6, or B12 within 3 months before surgery;\n* Severe hepatic or renal insufficiency (liver function: ALT\u002FAST \\> 3 times the upper limit of normal, or total bilirubin \\> 2 times the upper limit of normal; renal function: serum creatinine \\> 265 μmol\u002FL, or requiring long-term dialysis treatment);\n* Malignant tumors, severe hematological diseases (e.g., megaloblastic anemia, aplastic anemia), severe malnutrition (albumin \\\u003C 25 g\u002FL);\n* History of allergy to Compound Vitamin B preparations or placebo components; Pregnant women, lactating women, or those planning to become pregnant during the study period;\n* Currently participating in other interventional clinical trials;\n* Moderate to severe cognitive impairment without a fixed caregiver, unable to cooperate with treatment and follow-up;\n* Preoperatively diagnosed with severe infection, septicemia, or septic shock.",{"count":53,"type":22},[25],"This study is a multicenter, randomized controlled, double-blind, placebo-controlled parallel trial designed to evaluate the effect of perioperative supplementation with Compound Vitamin B on patients undergoing cardiovascular surgery. A total of 1,000 patients aged 18-80 years who are scheduled to receive cardiovascular surgeries such as coronary artery bypass grafting (CABG) and valve replacement will be enrolled. They will be randomly assigned at a 1:1 ratio to either the experimental group (perioperative supplementation with Compound Vitamin B tablets, once daily from 3 days before surgery to 6 months after surgery) or the control group (oral placebo), with both groups receiving standardized perioperative treatment.",[302,303],"Cardiovascular Surgical Procedures","Major Adverse Cardiovascular Events (MACE)",[305,306,307],"Compound Vitamin B","Cardiovascular Surgery","Major Adverse Cardiovascular Events","2026-01-09",{"date":310,"type":36},"2026-01-16",{"date":312,"type":22},"2026-02-01",{"date":222,"type":22},{"name":42,"class":43},2,{"id":317,"slug":318,"hasResults":12,"nctId":319,"briefTitle":320,"officialTitle":321,"acronym":4,"eligibilityCriteria":322,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":323,"enrollmentInfo":324,"targetDuration":4,"studyType":23,"phases":326,"briefSummary":327,"conditions":328,"keywords":330,"overallStatus":111,"whyStopped":4,"lastUpdateSubmitDate":333,"lastUpdatePostDateStruct":334,"startDateStruct":336,"completionDateStruct":338,"leadSponsor":340,"locationsCount":44},"100613758","impact-of-pre-ablation-prehabilitation-on-clinical-outcomes-and-cardiorespiratory-fitness-in-atrial-fibrillation-patients-100613758","NCT07270757","Impact of Pre-Ablation Prehabilitation on Clinical Outcomes and Cardiorespiratory Fitness in Atrial Fibrillation Patients","Impact of Pre-Ablation Prehabilitation on Clinical Outcomes and Cardiorespiratory Fitness in Patients With Atrial Fibrillation: A Randomized Controlled Trial","Inclusion Criteria:\n\n1. Aged 18-70 years\n2. Scheduled for first AF ablation\n3. NYHA class I-II\n4. LVEF ≥ 50%\n\nExclusion Criteria:\n\n1. Significant structural heart disease (e.g., severe valvular disease)\n2. Contraindications to CPET or exercise training\n3. Cognitive impairment preventing cooperation","70 Years",{"count":325,"type":22},100,[25],"The primary objective of this study is to compare the effects of a preoperative prehabilitation program versus usual care on post-procedural cardiorespiratory function and clinical outcomes in patients undergoing catheter ablation for atrial fibrillation.",[329],"Atrial Fibrillation (AF)",[331,332],"Atrial Fibrillation","Cardiac rehabilitation","2025-11-26",{"date":335,"type":36},"2025-12-08",{"date":337,"type":36},"2025-02-01",{"date":339,"type":22},"2026-03",{"name":42,"class":43},{"id":342,"slug":343,"hasResults":12,"nctId":344,"briefTitle":345,"officialTitle":346,"acronym":4,"eligibilityCriteria":347,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":323,"enrollmentInfo":348,"targetDuration":4,"studyType":23,"phases":349,"briefSummary":351,"conditions":352,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":354,"lastUpdatePostDateStruct":355,"startDateStruct":357,"completionDateStruct":359,"leadSponsor":361,"locationsCount":4},"100606178","early-phase-1--t-pd-1-ab-cells-in-the-treatment-of-malignant-meningioma-100606178","NCT07172178","γδ T-PD-1 Ab Cells in the Treatment of Malignant Meningioma","Anti-PD-1 Antibody Armored γδ T Cells in the Treatment of Malignant Meningioma, a Phase I Clinical Trail","Inclusion Criteria:\n\n1. The patient voluntarily signs the informed consent and can complete the follow-up examination, evaluation and treatment;\n2. Age 18-70 years old (both ends included), both male and female;\n3. The histopathological diagnosis was malignant solid tumor;\n4. Tumor recurrence is confirmed by imaging (MRI) or re-biopsy\u002Fsurgery;\n5. ECOG score 0-2;\n6. Expected survival ≥6 months;\n7. Have received chemotherapy or targeted therapy more than 4 weeks ago;\n8. Organ function requirements:\n\n   Bone marrow function: white blood cell count≥3×109, platelets ≥70×109\u002FL, a hemoglobin (Hb) ≥90g\u002FL; Liver function: total bilirubin ≤1.5 times the upper limit of normal (ULN); Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤3 times ULN; Renal function: serum creatinine level ≤1.5 ULN; Coagulation function: international normalized ratio (INR) does not exceed 1.5 times the upper limit of normal, and activated partial thromboplastin time (APTT) does not exceed 1.5 times the upper limit of normal.\n\n   Cardiac function: left ventricular ejection fraction (LVEF) \\> 55%\n9. Pregnant women of childbearing age must have a negative serum pregnancy test within 28 days before treatment. Any fertile male and female patients must agree to use effective contraceptive methods throughout the study and for at least 12 weeks after the last study administration.\n\nExclusion Criteria:\n\n1. Intolerance or allergy to any ingredient or similar drug in the treatment plan planned for this study;\n2. Major organ dysfunction:\n\n   Cardiac function: Left ventricular ejection fraction (LVEF) ≤ 55%, New York Heart Association (NYHA) grade III or IV congestive heart failure, QTc \\> 480 msec, other cardiac diseases as determined by the investigator to be unsuitable for inclusion.\n\n   Liver function: Child-Pugh liver function classification C or above. Pulmonary function: Severe respiratory failure affecting other organs.\n3. Uncontrolled epilepsy, severe bleeding risk (such as a recent history of cerebral hemorrhage).\n4. Active and\u002For uncontrolled infections (such as tuberculosis, sepsis, opportunistic infections, active hepatitis B virus (HBV) or active hepatitis C virus (HCV) infection, human immunodeficiency virus (HIV) infection, Treponema pallidum (TP) infection).\n5. Severe, uncontrolled systemic autoimmune or inflammatory diseases (such as systemic lupus erythematosus, rheumatoid arthritis, ulcerative colitis, Crohn's disease, and temporal arteritis, Guillain-Barré syndrome (GBS), amyotrophic lateral sclerosis (ALS)).\n6. Unstable systemic diseases: unstable angina pectoris, cerebrovascular accident or transient ischemia (within 6 months before screening), myocardial infarction (within 6 months before screening), grade III or IV cardiac dysfunction, refractory hypertension (refractory hypertension is defined as: after lifestyle improvement and using appropriate doses of ≥ 4 antihypertensive drugs (including diuretics), blood pressure cannot be effectively controlled after treatment for more than 1 month and still not controlled), severe arrhythmia requiring drug treatment, hepatic arrhythmia, liver disease, kidney disease or metabolic disorders.\n7. Patients with other malignant tumors.\n8. Major surgeries within 4 weeks before screening that were assessed by the investigator as unsuitable for inclusion.\n9. Participated in other interventional clinical studies within 30 days before enrollment.",{"count":205,"type":22},[350],"EARLY_PHASE1","This study intends to combine the advantages of γδ T cells and PD-1 monoclonal antibody to conduct an exploratory clinical study on the safety and efficacy of PD-1 antibody armored γδ T cells (γδ T-PD-1 Ab cells) in the treatment of malignant meningioma.",[353],"Malignant Meningioma","2025-09-11",{"date":356,"type":36},"2025-09-15",{"date":358,"type":22},"2025-10-15",{"date":360,"type":22},"2029-10",{"name":42,"class":43},{"id":363,"slug":364,"hasResults":12,"nctId":365,"briefTitle":366,"officialTitle":367,"acronym":368,"eligibilityCriteria":369,"healthyVolunteers":12,"sex":17,"minAge":370,"maxAge":176,"enrollmentInfo":371,"targetDuration":373,"studyType":180,"phases":4,"briefSummary":374,"conditions":375,"keywords":377,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":380,"lastUpdatePostDateStruct":381,"startDateStruct":383,"completionDateStruct":384,"leadSponsor":386,"locationsCount":4},"100603051","mechanisms-and-interventions-for-physical-activity-in-frail-cardiovascular-kidney-metabolic-syndrome-patients-a-temporal-self-regulation-approach-100603051","NCT07131488","Mechanisms and Interventions for Physical Activity in Frail Cardiovascular-kidney-metabolic Syndrome Patients: A Temporal Self-Regulation Approach","Research on the Mechanisms and Intervention Strategies for Physical Activity Promotion in Frail Patients With Cardiovascular-Kidney-Metabolic Syndrome From a Temporal Self-Regulation Perspective","CKM","Inclusion Criteria:\n\n* Aged ≥45 years and \\\u003C60 years;\n\nFrailty status assessed by Fried phenotype criteria, including those diagnosed with frailty or pre-frailty;\n\nMeeting AHA guideline criteria for Stage 1-2 CKM syndrome (diagnostic details in Table 1);\n\nAbility to communicate normally and use smartphones or wearable devices;\n\nWillingness to participate in surveys and follow-up;\n\nAdditional Note on PREVENT Equation:\n\nThe PREVENT equation, developed by the American Heart Association (AHA), is a cardiovascular disease (CVD) risk prediction tool. It calculates 10-year CVD risk based on:\n\nAge, sex\n\nTotal cholesterol, HDL-C\n\nSystolic blood pressure, BMI\n\neGFR\n\nHistory of diabetes, smoking\n\nUse of antihypertensive or lipid-lowering medications\n\nExclusion Criteria:\n\n* Severe cognitive impairment (e.g., MMSE score \\\u003C10 or clinical dementia diagnosis);\n\nSevere psychiatric\u002Fpsychological disorders (e.g., schizophrenia, major depressive disorder with suicidal ideation);\n\nAdvanced chronic diseases including:\n\nEnd-stage renal disease (eGFR \\\u003C15 mL\u002Fmin\u002F1.73m² or on dialysis)\n\nMetastatic cancer (stage IV per AJCC criteria)\n\nCardiorespiratory insufficiency (NYHA Class III-IV heart failure or COPD GOLD Stage D)\n\nSevere osteoarthritis (Kellgren-Lawrence Grade 4 with functional limitation)\n\nMajor surgery or acute illness within 3 months (e.g., myocardial infarction, stroke, or major trauma requiring hospitalization);\n\nPhysical disabilities impairing mobility (e.g., amputation, paralysis, or severe Parkinsonism with Hoehn \\& Yahr Stage ≥3).","45 Years",{"count":372,"type":22},614,"9 Months","Longitudinal physical activity data and associated factors were collected at baseline (diagnosis), 3-month, 6-month, and 9-month follow-ups in cardiovascular-kidney-metabolic syndrome patients.",[376],"Cardiovascular-kidney-metabolic Syndrome",[378,379],"Time-limited Self-regulation Theory","physical activity","2025-08-12",{"date":382,"type":36},"2025-08-20",{"date":382,"type":22},{"date":385,"type":22},"2026-10-12",{"name":42,"class":43},{"id":388,"slug":389,"hasResults":12,"nctId":390,"briefTitle":391,"officialTitle":392,"acronym":4,"eligibilityCriteria":393,"healthyVolunteers":51,"sex":17,"minAge":18,"maxAge":73,"enrollmentInfo":394,"targetDuration":4,"studyType":180,"phases":4,"briefSummary":396,"conditions":397,"keywords":399,"overallStatus":111,"whyStopped":4,"lastUpdateSubmitDate":402,"lastUpdatePostDateStruct":403,"startDateStruct":405,"completionDateStruct":407,"leadSponsor":409,"locationsCount":44},"100593204","diaphragmatic-function-and-respiratory-drive-in-osa-and-copd-100593204","NCT07003399","Diaphragmatic Function and Respiratory Drive in OSA and COPD","Diaphragmatic Morphofunction and Respiratory Drive in OSA and COPD: Insights From Ultrasound and EMG-based Cross-Sectional Analysis","Inclusion Criteria:\n\n1. Patients aged between 18 and 80 years.\n2. For OSA Group: Diagnosed obstructive sleep apnea with AHI ≥ 5 events\u002Fhour based on overnight polysomnography.\n3. For COPD Group: Diagnosed chronic obstructive pulmonary disease based on GOLD guidelines.\n4. For Overlap Group: Diagnosed both OSA (AHI ≥ 5) and COPD.\n5. For Control Group: Healthy volunteers with no known respiratory diseases or sleep disorders.\n6. Ability and willingness to provide informed consent for participation in the study.\n\nExclusion Criteria:\n\n1. Severe cardiovascular diseases (e.g., unstable angina, heart failure NYHA III\u002FIV).\n2. Severe hepatic or renal insufficiency.\n3. Neuromuscular diseases affecting respiratory muscles.\n4. Recent upper airway or thoracic surgery (within 3 months).\n5. Pregnancy or breastfeeding.\n6. Participants who cannot complete assessments due to cognitive impairment or poor cooperation.",{"count":395,"type":22},80,"This cross-sectional observational study aims to assess the diaphragmatic morphofunction and respiratory drive characteristics among patients with obstructive sleep apnea (OSA), chronic obstructive pulmonary disease (COPD), overlap syndrome (OS), and healthy controls. Using ultrasound imaging and surface diaphragm electromyography (EMGdi), the study will explore group differences in diaphragmatic morphology, function, and respiratory drive indicators, and evaluate their clinical significance in disease differentiation and severity assessment.",[398],"Obstructive Sleep Apnea",[398,400,401],"Chronic Obstructive Pulmonary Disease","Overlap Syndrome","2025-06-24",{"date":404,"type":36},"2025-06-25",{"date":406,"type":36},"2025-01-01",{"date":408,"type":22},"2025-08-31",{"name":42,"class":43},{"id":411,"slug":412,"hasResults":12,"nctId":413,"briefTitle":414,"officialTitle":415,"acronym":4,"eligibilityCriteria":416,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":73,"enrollmentInfo":417,"targetDuration":4,"studyType":23,"phases":418,"briefSummary":419,"conditions":420,"keywords":423,"overallStatus":111,"whyStopped":4,"lastUpdateSubmitDate":402,"lastUpdatePostDateStruct":426,"startDateStruct":428,"completionDateStruct":429,"leadSponsor":431,"locationsCount":44},"100573624","optic-nerve-injury-in-obstructive-sleep-apnea-patients-100573624","NCT06748703","Optic Nerve Injury in Obstructive Sleep Apnea Patients","Optic Nerve Injury and the Effect of CPAP Treatment in Obstructive Sleep Apnea Patients","Inclusion Criteria:\n\n1. Patients aged between 18 and 80 years.\n2. Diagnosed with Obstructive Sleep Apnea Hypopnea Syndrome (OSAHS)(apnea-hypopnea index≥5\u002Fh).\n3. First-time diagnosis, with no previous surgical interventions or CPAP treatment for OSA.\n4. Ability and willingness to provide informed consent for participation in the study.\n\nExclusion Criteria:\n\n1. History of severe stroke or cerebral hemorrhage, or presence of neurological or psychiatric conditions that could affect study results.\n2. Presence of active malignancies or other severe underlying diseases, such as severe liver or kidney dysfunction. Diagnosed with diabetes or other significant vascular diseases.\n3. Presence of severe chronic obstructive pulmonary disease (COPD), severe asthma, severe pulmonary hypertension, or heart failure caused by any condition.\n4. Pregnancy or having other conditions that make participation in this study unsuitable.\n5. Extremely debilitated patients or those with severe underlying conditions.",{"count":395,"type":22},[25],"Ischemic optic neuropathy (ION) is damage to the optic nerve caused by ischemia and hypoxia of the optic nerve due to an impairment of the blood supply to the optic nerve from the arteries. Obstructive Sleep Apnea Hypoventilation Syndrome (OSAHS) is a sleep-breathing disorder characterized by recurrent upper airway obstruction and apnea during sleep, leading to recurrent intermittent hypoxemia with fragmented sleep and daytime sleepiness. Due to the lack of accurate methods to evaluate blood flow, the correlation between the two is unclear and uncertain. The study will enroll 80 patients from the First Affiliated Hospital of Nanjing Medical University and categorize them into mild, moderate, and severe OSA groups according to their apnea-hypopnea index (AHI). Participants will undergo a baseline evaluation, including polysomnography (PSG) and ophthalmologic examinations such as optic nerve and macular blood flow OCT, visual acuity, refraction, intraocular pressure, and visual fields. Eligible patients will be treated with CPAP for 3 months, after which their PSG and ophthalmologic examination-related results will be re-evaluated to assess treatment efficacy.",[421,422],"Obstructive Sleep Apnea (OSA)","Ischemic Optic Neuropathy\u002FOptic Nerve Stroke",[398,424,425],"Nonarteritic Ischemic Optic Neuropathy","CPAP treatment",{"date":427,"type":36},"2025-06-27",{"date":406,"type":36},{"date":430,"type":22},"2026-01-31",{"name":42,"class":43},{"id":433,"slug":434,"hasResults":12,"nctId":435,"briefTitle":436,"officialTitle":437,"acronym":4,"eligibilityCriteria":438,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":73,"enrollmentInfo":439,"targetDuration":4,"studyType":180,"phases":4,"briefSummary":441,"conditions":442,"keywords":443,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":447,"lastUpdatePostDateStruct":448,"startDateStruct":450,"completionDateStruct":452,"leadSponsor":454,"locationsCount":44},"100579563","precision-osa-therapy-based-on-phenotypes-and-endotypes-100579563","NCT06825923","Precision OSA Therapy Based on Phenotypes and Endotypes","Precise Intervention of Obstructive Sleep Apnea Based on Phenotypic Characteristics and Endotypic Mechanisms","Inclusion Criteria:\n\n1. Patients aged between 18 and 80 years.\n2. Diagnosed with Obstructive Sleep Apnea (OSA)(apnea-hypopnea index≥5\u002Fh).\n3. First-time diagnosis, with no previous surgical interventions or CPAP treatment for OSA.\n4. Ability and willingness to provide informed consent for participation in the study.\n\nExclusion Criteria:\n\n1. History of severe stroke or cerebral hemorrhage, or presence of neurological or psychiatric conditions that could affect study results.\n2. Presence of active malignancies or other severe underlying diseases, such as severe liver or kidney dysfunction. Diagnosed with diabetes or other significant vascular diseases.\n3. Presence of severe chronic obstructive pulmonary disease (COPD), severe asthma, severe pulmonary hypertension, or heart failure caused by any condition.\n4. Pregnancy or having other conditions that make participation in this study unsuitable.\n5. Extremely debilitated patients or those with severe underlying conditions.",{"count":440,"type":22},200,"Analyzing the phenotypic and endotypic characteristics of Sleep Apnea, along with DISE obstruction situations, is crucial for precise diagnosis and treatment. In this study, we aim to construct and apply a multidimensional predictive model based on four aspects: basic physiological characteristics of OSA, clinical phenotypes, mechanistic endotypes, and DISE obstruction levels. The study will begin by categorizing the clinical phenotypes; subsequently, it will quantify endotypic indicators based on PSG signal information and construct the PALM scale for Chinese individuals. Following this, a comprehensive clinical profile and a treatment efficacy prediction model for OSA patients will be built based on the results from the aforementioned multidimensional data.",[398],[398,444,445,446],"PALM","Phenotype","Endotype","2025-02-09",{"date":449,"type":36},"2025-02-13",{"date":451,"type":22},"2025-07-01",{"date":453,"type":22},"2029-12-31",{"name":42,"class":43},{"id":456,"slug":457,"hasResults":12,"nctId":458,"briefTitle":459,"officialTitle":460,"acronym":4,"eligibilityCriteria":461,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":462,"targetDuration":4,"studyType":180,"phases":4,"briefSummary":464,"conditions":465,"keywords":467,"overallStatus":111,"whyStopped":4,"lastUpdateSubmitDate":472,"lastUpdatePostDateStruct":473,"startDateStruct":474,"completionDateStruct":476,"leadSponsor":478,"locationsCount":44},"100579470","prediction-of-risk-of-vascular-structural-damage-in-patients-with-large-vessel-vasculitis-lvv-based-on-petmra-image-evaluation-system-100579470","NCT06824714","Prediction of Risk of Vascular Structural Damage in Patients With Large Vessel Vasculitis (LVV) Based on PET\u002FMRA Image Evaluation System","A Prospective, Observational Study on Prediction of Risk of Vascular Structural Damage in Patients With Large Vessel Vasculitis(LVV) Based on PET\u002FMRA Image Evaluation System","Inclusion Criteria:\n\n1. Clinically suspected or confirmed LVV and willing to undergo PET\u002FMRA\n2. Compliance with long-term follow-up\n3. Sign informed consent.\n\nExclusion Criteria:\n\n1. Patients with other serious cardiovascular and cerebrovascular diseases, malignant tumors, infectious diseases, severe renal insufficiency.\n2. Severe mental disorders, severe claustrophobia unable to cooperate with the examination.\n3. Patients equipped with cardiac pacemaker, artificial heart valve, ferromagnetic vascular clamp after vascular surgery, aneurysm clamp, artificial cochlea, insulin pump and other drug dosage control devices, steel nail plate and other metal internal fixation, artificial joint, electronic eye, artificial eye.\n4. Allergic to contrast medium.\n5. Pregnant or lactating women.\n\nWithdrawal criteria:\n\n1. Any exclusion criteria emerged during patient follow-up.\n2. Voluntarily withdrew from the study.",{"count":463,"type":22},150,"Large vessel vasculitis (LVV) causes vascular inflammation, leading to serious complications such as aneurysm formation and stroke. It is difficult to identify the inflammation of the vessel wall by the current imaging methods, thus affecting the timing of treatment and selection of treatment options. Improved examination methods to determine disease activity are highly needed to guide treatment.",[466],"Large Vessel Vasculitis",[466,468,469,470,471],"PET","MRA","SUVmax","TBA","2025-02-07",{"date":449,"type":36},{"date":475,"type":36},"2024-01-01",{"date":477,"type":22},"2028-07-01",{"name":42,"class":43},{"id":480,"slug":481,"hasResults":12,"nctId":482,"briefTitle":483,"officialTitle":484,"acronym":4,"eligibilityCriteria":485,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":323,"enrollmentInfo":486,"targetDuration":4,"studyType":180,"phases":4,"briefSummary":487,"conditions":488,"keywords":490,"overallStatus":111,"whyStopped":4,"lastUpdateSubmitDate":406,"lastUpdatePostDateStruct":494,"startDateStruct":496,"completionDateStruct":498,"leadSponsor":500,"locationsCount":315},"100574823","neural-changes-in-stroke-patients-during-challenging-walking-tasks-100574823","NCT06764290","Neural Changes in Stroke Patients During Challenging Walking Tasks.","Neural Mechanism Changes in Stroke Patients During Challenging Environments","Inclusion Criteria:\n\n* First-time occurrence of stroke confirmed by computed tomography or magnetic resonance imagingClinical diagnosis of stroke\n* Disease duration of more than 14 days， less than 1 year\n* Able to walk independently but with a lingering abnormal gait\n\nExclusion Criteria:\n\n* Lesions accumulate in the brainstem\n* Lesions accumulate in the cerebellum\n* Impaired vision\n* Severe cognitive impairment",{"count":99,"type":22},"For stroke patients, a challenging, unfamiliar, and more difficult task may increase the likelihood of brain activation to stimulate recovery. Pedal walking and walking with eyes-covered are both difficult and challenging tasks for stroke patients. The investigators intend to study the biomechanics and neural mechanisms of challenging pedal walking and walking with eyes covered.\n\nStroke participants will wear electroencephalogram electrode caps and perform three tasks: walking on a flat surface for 60 seconds, walking on pedal for 60 seconds, and walking with eyes covered for 60 seconds.",[489],"Stroke",[491,492,493],"Electroencephalography","gait rehablitation","challenging task",{"date":495,"type":36},"2025-01-08",{"date":497,"type":36},"2024-04-01",{"date":499,"type":22},"2025-02-28",{"name":42,"class":43},{"id":502,"slug":503,"hasResults":12,"nctId":504,"briefTitle":505,"officialTitle":506,"acronym":4,"eligibilityCriteria":507,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":508,"targetDuration":4,"studyType":180,"phases":4,"briefSummary":510,"conditions":511,"keywords":4,"overallStatus":111,"whyStopped":4,"lastUpdateSubmitDate":515,"lastUpdatePostDateStruct":516,"startDateStruct":518,"completionDateStruct":520,"leadSponsor":522,"locationsCount":315},"100572212","prospective-study-of-classification-and-activity-assessment-of-psoriatic-arthritis-based-on-power-doppler-pd-ultrasonography-pdus-100572212","NCT06730334","Prospective Study of Classification and Activity Assessment of Psoriatic Arthritis Based on Power Doppler (PD) Ultrasonography (PDUS)","A Single Centre Prospective Cohort Study of Classification and Activity Assessment of Psoriatic Arthritis Based on Power Doppler (PD) Ultrasonography (PDUS)","Inclusion Criteria:\n\n* PsA patients as defined by CASPAR criteria\n* Patients must be able to comply with the visit schedule, treatment plan, laboratory tests and other study procedures\n* Patients must be given informed consent\n\nExclusion Criteria:\n\n* History of other arthritis within the last 12 months\n* Concomitant disease with acute or chronic infectious diseases\n* Pregnancy or laction\n* Poorly tolerated with venipuncture required for blood sampling during the study",{"count":509,"type":22},400,"Psoriatic arthritis (PsA) is a complex inflammatory disease with heterogeneous clinical features, which complicates psoriasis in 30% of patients. PsA involves multiple tissues and clinical domains including skins and nails as well as arthritis, spondylitis, enthesitis, and dactylitis. Power Doppler (PD) ultrasonography (PDUS) is a sensitive non-invasive imaging technology used to assess disease activity and treatment response in PsA. This is a prospective, observational, open-label study to investigate disease activity, therapeutic response and bone destruction based on ultrasonography findings in patients with PsA.",[512,513,514],"Psoriatic Arthritis","Secukinumab","Ultrasonography","2024-12-18",{"date":517,"type":36},"2024-12-20",{"date":519,"type":36},"2023-09-01",{"date":521,"type":22},"2028-06-01",{"name":42,"class":43},{"id":524,"slug":525,"hasResults":12,"nctId":526,"briefTitle":527,"officialTitle":528,"acronym":529,"eligibilityCriteria":530,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":73,"enrollmentInfo":531,"targetDuration":4,"studyType":23,"phases":532,"briefSummary":533,"conditions":534,"keywords":539,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":543,"lastUpdatePostDateStruct":544,"startDateStruct":546,"completionDateStruct":548,"leadSponsor":549,"locationsCount":44},"100572079","protective-effect-of-eecp-against-negative-inflammatory-response-and-organ-dysfunction-after-cardiovascular-surgery-100572079","NCT06728605","Protective Effect of EECP Against Negative Inflammatory Response and Organ Dysfunction After Cardiovascular Surgery","Protective Effect of Enhanced External Counterpulsation Against Negative Inflammatory Response and Organ Dysfunction After Cardiovascular Surgery","PANDA","Inclusion Criteria:\n\n* Age \\> 18 years;\n* Patients with Stable angina pectoris, unstable angina pectoris, acute myocardial infarction, congestive heart failure, cardiogenic shock;\n* Patients chronic heart failure;\n* Patients are ready to received cardiovascular surgery during this hospital admission.\n* Patients agree to participate in the study and sign an informed consent form.\n\nExclusion Criteria:\n\n1\\. Moderate to severe aortic insufficiency; 2. Dissection aneurysm; 3. Significant pulmonary hypertension; 4, A variety of bleeding diseases or bleeding tendencies, or use anticoagulants, INR\\>2.0; 5, active phlebitis, venous thrombosis; 6. There is an infection in the counterpulsating limb; 7. Uncontrolled hyperhypertension (\\>170\u002F110mmHg); 8. Uncontrolled arrhythmias: frequent premature beats, rapid atrial fibrillation, etc.\n\n9\\. Pregnancy.",{"count":509,"type":22},[25],"Enhanced external counterpulsation (EECP) is a noninvasive, non-pharmacologic intervention proven to increase nitric oxide bioavailability in patients with coronary artery disease. Although EECP showed short-term effects in improving coronary flow in patients with coronary slow flow, whether such improvement is durable remains uncertain, and the relationships between such improvement and changes in multiple organ functions as well as inflammatory markers have not been elucidated. The purpose of this study will be to evaluate the potential clinical benefits of EECP on organ function and proinflammatory cytokine concentrations during post-acute sequela of cardiovascular surgery.",[535,536,537,538],"Coronary Heart Disease (CHD)","Cardio-pulmonary Bypass","Congestive Heart Failure Chronic","Cardiogenic Shock Acute",[540,541,542],"cardiac surgery","cardiopulmonary bypass","cardiogenic shock","2024-12-10",{"date":545,"type":36},"2024-12-11",{"date":547,"type":22},"2025-12-31",{"date":547,"type":22},{"name":42,"class":43},{"id":551,"slug":552,"hasResults":12,"nctId":553,"briefTitle":554,"officialTitle":554,"acronym":529,"eligibilityCriteria":555,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":556,"enrollmentInfo":557,"targetDuration":4,"studyType":23,"phases":558,"briefSummary":559,"conditions":560,"keywords":4,"overallStatus":111,"whyStopped":4,"lastUpdateSubmitDate":543,"lastUpdatePostDateStruct":562,"startDateStruct":564,"completionDateStruct":566,"leadSponsor":568,"locationsCount":569},"100416178","protective-effect-of-statin-against-negative-cardiovascular-remodeling-and-organ-dysfunction-after-acute-aortic-syndrome-surgery-panda-iii-100416178","NCT04699279","Protective Effect of Statin Against Negative Cardiovascular Remodeling and Organ Dysfunction After Acute Aortic Syndrome Surgery (PANDA III)","Inclusion Criteria:\n\n* (1) Patients with aortic dissection\u002Fulceration\u002Fintermural hematoma\u002Faortic aneurysm who underwent aortic arch replacement or endoluminal isolation or hybrid therapy;\n* (2) Paitents without clinically significant hyperlipidemia but with cardiovascular disease risk factors (such as male ≥45 years old, female ≥55 years old, hypertension, diabetes, chronic kidney disease, obesity, low HDL cholesterol, smoking, alcohol consumption, family history of early onset ischemic cardiovascular disease) and no previous use of statins;\n* (3) Patients are between 18 and 85 years old, male or female;\n* (4) Agree to participate in the study and sign the informed consent.\n\nExclusion Criteria:\n\n* (1) Patients with allergy to statins;\n* (2) patients with active liver disease;\n* (3) patients with myopathy;\n* (4) Lactating women and pregnant women;\n* (5) Patients with mental diseases, drug and alcohol dependence;\n* (6) Refuse to participate in the study or sign the informed consent.","85 Years",{"count":275,"type":22},[25],"Acute Aortic Syndrome (AAS)\u002FAortic Aneurysm is a common feature of aortic wall events, including aortic dissection, intramural hematoma, aortic ulceration and aortic trauma, and occurs in up to 35 cases per 100,000 cases per year between the ages of 65 and 75 years. Increased levels of the inflammatory biomarker high-sensitivity C-reactive protein predict cardiovascular events. Since statins lower levels of high-sensitivity C-reactive protein as well as cholesterol, the authors hypothesized that people with acute aortic syndrome but without hyperlipidemia might benefit from statin treatment.",[257,561],"Aortopathy",{"date":563,"type":36},"2024-12-13",{"date":565,"type":36},"2021-01-01",{"date":567,"type":22},"2024-12-31",{"name":42,"class":43},5,{"id":571,"slug":572,"hasResults":12,"nctId":573,"briefTitle":574,"officialTitle":575,"acronym":4,"eligibilityCriteria":576,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":577,"targetDuration":4,"studyType":23,"phases":579,"briefSummary":580,"conditions":581,"keywords":584,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":586,"lastUpdatePostDateStruct":587,"startDateStruct":589,"completionDateStruct":590,"leadSponsor":591,"locationsCount":315},"100571677","protective-effect-of-angong-niuhuang-against-negative-inflammatory-response-and-neurologic-dysfunction-after-cardiovascular-surgery-100571677","NCT06723366","Protective Effect of Angong Niuhuang Against Negative Inflammatory Response and Neurologic Dysfunction After Cardiovascular Surgery","Protective Effect of Angong Niuhuang Against Negative Inflammatory Response and Neurologic Dysfunction After Cardiovascular Surgery (PANDA X)","Inclusion Criteria:\n\n* (1) an age \\> 18 years,\n* (2) underwent cardiovascular surgery,\n* (3) diagnosis of acute neurologic dysfunction, including but not limited acute cerebral infarction of the internal carotid artery system,\n* (4) a National Institutes of Health Stroke Scale (NIHSS) score ranging from 10 to 20,\n* (5) a time from symptom onset to randomization within 36 h,\n* (6) provision of informed consent.\n\nExclusion Criteria:\n\n* (1) not suitable for taking ANP after the dialectical process by a traditional Chinese medical doctor,\n* (2) received ANP within 1 month before stroke onset,\n* (3) liver failure,\n* (4) declined to participate in this study.",{"count":578,"type":22},120,[25],"Neurologic Dysfunction is one of the main factors contributing to poor outcomes in cardiac surgery patients, except for heart failure. Atherosclerosis of the aorta, a history of cerebral infarction, and cervical artery disease are common clinical risk factors for cerebral neurological dysfunction after cardiac surgery. Results of preclinical studies suggested that Angong Niuhuang Pills (ANPs), a traditional Chinese patent medicine, including realgar, cinnabaris, Bovis Calculus, artificial Moschus, and powdered buffalo horn extract, decreased infarct volume and cerebral edema, and presented anti- atherosclerosis and cardio-protective effects in clinical and preclinical studies. The PANDA X trial is designed as a pilot study to explore the safety and efficacy of ANP in patients with moderate-to-severe neurologic dysfunction after cardiovascular surgery.",[536,306,582,583],"Cerebral Protection","Brain Injury",[585,541],"Inflammatory Response","2024-12-09",{"date":588,"type":36},"2024-12-12",{"date":406,"type":22},{"date":547,"type":22},{"name":42,"class":43},{"id":593,"slug":594,"hasResults":12,"nctId":595,"briefTitle":596,"officialTitle":596,"acronym":529,"eligibilityCriteria":597,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":598,"targetDuration":4,"studyType":23,"phases":599,"briefSummary":600,"conditions":601,"keywords":604,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":586,"lastUpdatePostDateStruct":606,"startDateStruct":607,"completionDateStruct":608,"leadSponsor":610,"locationsCount":315},"100572248","protective-effect-of-pcsk9-inhibitor-against-negative-inflammatory-response-and-organ-dysfunction-after-coronary-artery-bypass-grafting-panda-viii-100572248","NCT06730802","Protective Effect of PCSK9 Inhibitor Against Negative Inflammatory Response and Organ Dysfunction After Coronary Artery Bypass Grafting (PANDA VIII)","Inclusion Criteria:\n\n* Male or female ≥ 18 years of age\n* Patients with myocardial ischemic syndromes (with any of the following):\n* Patients are ready to undergo coronary artery bypass grafting (CABG) with 1 month;\n* Participate voluntarily and sign an informed consent\n\nExclusion Criteria:\n\ni. Pregnant and lactating women ii. During the study period and within 3 months of receiving the last dose of the study drug, women with fertility intentions and men unwilling to use effective contraceptive methods iii. Have used PCSK9 inhibitors within 3 months before enrollment, or have a history of severe allergic reactions to PCSK9 inhibitors iv. Severe infections requiring intravenous antibiotics v. HIV-positive or history of acquired immunodeficiency syndrome (AIDS) vi. With cognitive impairment or psychiatric illnesses",{"count":509,"type":22},[25],"This is a multi-center, randomized controlled study to investigate whether early offering PCSK9 inhibitor can protect against negative inflammatory response and organ dysfunction after coronary artery bypass grafting (CABG). Subjects with myocardial ischaemic syndromes (MIS) will be enrolled in this study after consent information. After randomization, the control group will receive standard therapy, while the experiment group will receive first PCSK9 inhibitor before CABG, then twice a month until 3 months later. Six month after CABG, CRP will be used to evaluate inflammation, and echocardiography and coronary CTA will be used to evaluate cardiovascular function.",[602,603],"Myocardial Ischaemic Syndrome","Coronary Heart Disease",[281,605],"CABG",{"date":588,"type":36},{"date":406,"type":22},{"date":609,"type":22},"2026-12-31",{"name":42,"class":43},""]